UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

Impact of exhaled nitric oxide measurements on treatment decisions in an asthma specialty clinic

Annals of allergy, asthma, & immunology, 2014-12, Vol.113 (6), p.619-623

2014

Volltextzugriff (PDF)

Measuring Exhaled Nitric Oxide (FeNO) Improves Assessment of Airway Inflammation and Guides Stepwise Treatment Decisions

Journal of allergy and clinical immunology, 2017-02, Vol.139 (2), p.AB196-AB196

2017

Volltextzugriff (PDF)

Asthma Management Costs With Feno In Addition To Standard Guidelines

Journal of allergy and clinical immunology, 2014-02, Vol.133 (2), p.AB85-AB85

2014

Volltextzugriff (PDF)

Validation of a New Portable Exhaled Nitric Oxide Analyzer, NIOX VERO®: Randomized Studies in Asthma

Pulmonary therapy, 2017-06, Vol.3 (1), p.207-218

2017

Volltextzugriff (PDF)

Clinical Outcomes of Subjects with Non-Specific Respiratory Symptoms and High Feno Who Were Not Diagnosed with Asthma – A Retrospective Review of Outcomes 6 Months Following the Initial Evaluation

Journal of allergy and clinical immunology, 2013-02, Vol.131 (2), p.AB64-AB64

2013

Volltextzugriff (PDF)

Relationship of Fractional Exhaled Nitric Oxide Levels (FeNO) to GOLD Classification and Underlying Disease Classification in COPD

Chest, 2013, Vol.144 (4), p.719A-719A

2013

Volltextzugriff (PDF)

Agreement Between the 6 Seconds and 10 Seconds Exhalation Modes When Measuring Fractional Exhaled Nitric Oxide in Children Aged 4-6 Years With the NIOX VERO Device

Chest, 2017-10, Vol.152 (4), p.A842-A842

2017

Volltextzugriff (PDF)

Cilomilast for COPD

Chest, 2006-01, Vol.129 (1), p.56-66

2006

Volltextzugriff (PDF)

Cilomilast for COPD : Results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4

Chest, 2006, Vol.129 (1), p.56-66

2006

Volltextzugriff (PDF)

Successful Fractional Exhaled Nitric Oxide Measurements with NIOX VERO using 6- and 10-s Exhalation Modes in Children with Asthma Aged 4–10 Years: A Randomized Study

Pulmonary therapy, 2017-06, Vol.3 (1), p.139-148

2017

Volltextzugriff (PDF)

The NIOX VERO Differentiates Primary Ciliary Dyskinesia From Healthy Children Using Nasal Nitric Oxide Measurements

Chest, 2017-10, Vol.152 (4), p.A594-A594

2017

Volltextzugriff (PDF)

Higher 30-day and 60-day readmissions among patients who refuse post acute care services

The American journal of managed care, 2015-06, Vol.21 (6), p.424-433

2015

Volltextzugriff (PDF)

Successful Electronic Implementation of Discharge Referral Decision Support Has a Positive Impact on 30- and 60-day Readmissions

Research in nursing & health, 2015-04, Vol.38 (2), p.102-114

2015

Volltextzugriff (PDF)

Misleading data analyses in salmeterol (SMART) study – GlaxoSmithKline's reply

The Lancet (British edition), 2005-10, Vol.366 (9493), p.1262-1262

Rickard, Kathy A

2005

Volltextzugriff (PDF)

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial

Journal of allergy and clinical immunology, 2001-03, Vol.107 (3), p.461-468

2001

Volltextzugriff (PDF)

Misleading data analyses in salmeterol (SMART) study

The Lancet (British edition), 2005-10, Vol.366 (9493), p.1261-1262

2005

Volltextzugriff (PDF)

Misleading data analyses in salmeterol (SMART) study/GlaxoSmithKline's reply

The Lancet (British edition), 2005-10, Vol.366 (9493), p.1261

2005

Volltextzugriff (PDF)

Abstracts from the 3rd International Severe Asthma Forum (ISAF)

Clinical and translational allergy, 2017-05, Vol.7 (S2), p.1-n/a, Article 14

2017

Volltextzugriff (PDF)

A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma

Journal of allergy and clinical immunology, 1999-05, Vol.103 (5), p.796-803

1999

Volltextzugriff (PDF)

28 Changes in PEF measurements correlated with changes in patient-related symptom assessments in asthma patients

Journal of allergy and clinical immunology, 2000, Vol.105 (1), p.S10-S10

2000

Volltextzugriff (PDF)

40 Low-dose inhaled fluticasone propionate provides greater asthma symptom control as compared with oral zafirlukast in patients with persistent asthma

Journal of allergy and clinical immunology, 2000, Vol.105 (1), p.S14-S14

2000

Volltextzugriff (PDF)

41 Greater improvement in pulmonary function with low-dose inhaled fluticasone propionate as compared with oral zafirlukast in patients with persistent asthma

Journal of allergy and clinical immunology, 2000, Vol.105 (1), p.S14-S14

2000

Volltextzugriff (PDF)

Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma

The American journal of managed care, 1998-11, Vol.4 (11), p.1579

1998

Volltextzugriff (PDF)

A Cost Comparison of β2-Agonist Bronchodilators Is Not a Cost-Effectiveness Comparison

Pharmacotherapy, 1996-05, Vol.16 (3), p.484-485

1996

Volltextzugriff (PDF)

A cost comparison of beta 2-agonist bronchodilators is not a cost-effectiveness comparison

Pharmacotherapy, 1996-05, Vol.16 (3), p.484-485

1996

Volltextzugriff (PDF)

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(38)
Tagungsberichte
(1)

Sprache

Englisch
(39)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of exhaled nitric oxide measurements on treatment decisions in an asthma specialty clinic

Measuring Exhaled Nitric Oxide (FeNO) Improves Assessment of Airway Inflammation and Guides Stepwise Treatment Decisions

Asthma Management Costs With Feno In Addition To Standard Guidelines

Validation of a New Portable Exhaled Nitric Oxide Analyzer, NIOX VERO®: Randomized Studies in Asthma

Clinical Outcomes of Subjects with Non-Specific Respiratory Symptoms and High Feno Who Were Not Diagnosed with Asthma – A Retrospective Review of Outcomes 6 Months Following the Initial Evaluation

Relationship of Fractional Exhaled Nitric Oxide Levels (FeNO) to GOLD Classification and Underlying Disease Classification in COPD

Agreement Between the 6 Seconds and 10 Seconds Exhalation Modes When Measuring Fractional Exhaled Nitric Oxide in Children Aged 4-6 Years With the NIOX VERO Device

Cilomilast for COPD

Cilomilast for COPD : Results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4

Successful Fractional Exhaled Nitric Oxide Measurements with NIOX VERO using 6- and 10-s Exhalation Modes in Children with Asthma Aged 4–10 Years: A Randomized Study

The NIOX VERO Differentiates Primary Ciliary Dyskinesia From Healthy Children Using Nasal Nitric Oxide Measurements

Higher 30-day and 60-day readmissions among patients who refuse post acute care services

Successful Electronic Implementation of Discharge Referral Decision Support Has a Positive Impact on 30- and 60-day Readmissions

Misleading data analyses in salmeterol (SMART) study – GlaxoSmithKline's reply

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial

Misleading data analyses in salmeterol (SMART) study

Misleading data analyses in salmeterol (SMART) study/GlaxoSmithKline's reply

Abstracts from the 3rd International Severe Asthma Forum (ISAF)

A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma

28 Changes in PEF measurements correlated with changes in patient-related symptom assessments in asthma patients

40 Low-dose inhaled fluticasone propionate provides greater asthma symptom control as compared with oral zafirlukast in patients with persistent asthma

41 Greater improvement in pulmonary function with low-dose inhaled fluticasone propionate as compared with oral zafirlukast in patients with persistent asthma

Efficacy, safety, and impact on quality of life of salmeterol in patients with moderate persistent asthma

A Cost Comparison of β2-Agonist Bronchodilators Is Not a Cost-Effectiveness Comparison

A cost comparison of beta 2-agonist bronchodilators is not a cost-effectiveness comparison

Suchergebnisse filtern